The current COVID-19 epidemic is basically stable, and various drugs and related research and development are underway in an orderly manner. So for the current A-shares, which stocks are COVID-19 stocks? Which drugs produced by listed companies are used for this disease?
What are the new coronavirus concept stocks?
The specific drugs currently on the market to treat new coronavirus pneumonia are mainly chloroquine phosphate and fapi There are three types of drugs: Lavir and Remdesivir, so the new coronavirus concept stocks are mainly divided into three drug categories. Among them, the chloroquine phosphate concept stocks are Shanghai Pharmaceuticals, Cap Biotech, and Rundu Shares, and Fapira Wei Ze has only one stock of Hisun Pharmaceutical, while Remdesivir has stocks such as Borui Pharmaceuticals, Porton Holdings, Yongtai Technology and Yaben Chemical.
1 Shanghai Pharmaceuticals: In addition to the original manufacturer, the company has the exclusive domestic approval for hydroxychloroquine preparations, with a market share of over 76%. It is one of the company’s key products. Currently, the inventory is sufficient and production is ongoing.
2 Kaipu Biotech: Based on its antiviral research on chloroquine phosphate, the company has obtained national invention patent authorization (Patent name: A chloroquine gel and its preparation method and application, patent number: ZL201811474701. 3), and developed the drug chloroquine phosphate gel.
3 Rundu Co., Ltd. currently only produces piperaquine phosphate API, which is one of the anti-malarial drugs together with chloroquine phosphate.
4 Hisun Pharmaceutical: On February 15, Hisun Pharmaceutical announced that Favipiravir tablets were officially approved for marketing by the State Food and Drug Administration with conditions for the treatment of new or re-epidemic influenza in adults.
5 Borui Pharmaceuticals: The project orders between the company and Gilead are already being executed. The company will perform its business as a supplier in strict accordance with commercial terms, including but not limited to trade secret protection.
6 Porton shares: The company began to provide customized development and production (CDMO) services for Gilead Sciences’ antiviral drug Remdesivir (Remdesivir) in 2015, and delivered it to clinical trials multiple times in 2016. Advanced intermediates in demand.
7 Yongtai Technology: The company has cooperated with Gilead for many years in product development and supply, including intermediates for the anti-hepatitis C virus drug sofosbuvir.
8 Yaben Chemical: The company currently has some of the key intermediates of Remdesivir in stock, which will be delivered immediately. At the same time, it is actively preparing for production and supplying customers in a timely manner.
To sum up, these are the most COVID-19-related stocks on the market right now, and these stocks will benefit from the continued production of follow-up drugs.